RBC Life Sciences (RBCL) 10-K 27 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 28, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'RBC LIFE SCIENCES, INC.	'	'
Entity Central Index Key	'0000830052	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Amendment Flag	'false	'	'
Entity Common Stock, Shares Outstanding	'	2,212,250	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$1,329,904

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets	'	'
Cash and cash equivalents	$3,745,684	$3,896,087
Accounts receivable, net of allowance for doubtful accounts of $28,000 and $27,417, respectively	907,287	877,275
Inventories	5,141,509	5,084,900
Deferred income taxes	429,640	462,088
Prepaid expenses and other current assets	793,548	833,458
Total current assets	11,017,668	11,153,808
Property and equipment, net of accumulated depreciation	4,169,078	4,488,374
Goodwill	2,263,458	2,298,020
Other intangible assets, net of accumulated amortization	37,979	43,936
Other assets	45,327	30,283
Total assets	17,533,510	18,014,421
Current liabilities	'	'
Accounts payable, trade	1,608,000	1,495,194
Accrued liabilities	1,156,818	1,111,131
Current maturities of long-term obligations	212,474	196,678
Deferred revenue	3,677,893	3,230,506
Total current liabilities	6,655,185	6,033,509
Long-term obligations, less current maturities	1,136,347	1,348,821
Deferred income taxes	727,660	1,116,593
Commitments and contingencies	'	'
Shareholders' equity	'	'
Common stock, $0.001 par value; authorized 50,000,000 shares; 2,212,250 and 2,222,883 shares issued and outstanding in 2013 and 2012, respectively. (See Note B regarding Stock Splits)	2,212	2,223
Additional paid-in capital. (See Note B regarding Stock Splits)	13,711,522	13,708,736
Accumulated deficit	-4,814,281	-4,314,278
Accumulated other comprehensive income	114,865	118,817
Total shareholders' equity	9,014,318	9,515,498
Total liabilities and shareholders' equity	$17,533,510	$18,014,421

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets	'	'
Less allowance for doubtful accounts	$28,000	$27,417
Shareholders' equity	'	'
Common stock par value (in dollars per share)	$0.00	$0.00
Common stock shares authorized	50,000,000	50,000,000
Common stock shares issued	2,212,250	2,222,883
Common stock shares outstanding	2,212,250	2,222,883

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]	'	'
Net sales	$25,470,934	$25,160,172
Cost of sales	13,459,279	12,528,218
Gross profit	12,011,655	12,631,954
Operating expenses	'	'
General and administrative	9,344,628	9,808,930
Distributor commissions	2,785,568	3,214,664
Depreciation and amortization	506,083	515,017
Casualty gain	0	-443,064
Total operating expenses	12,636,279	13,095,547
Operating loss	-624,624	-463,593
Interest expense	111,617	126,333
Loss before income taxes	-736,241	-589,926
Income tax benefit	-236,236	-228,490
Net loss	-500,005	-361,436
Foreign currency translation adjustment	-3,952	-24,733
Comprehensive loss	($503,957)	($386,169)
Basic (usd per share)	($0.23)	($0.16)
Diluted (usd per share)	($0.23)	($0.16)
Basic (shares)	2,218,757	2,222,883
Diluted (shares)	2,218,757	2,222,883

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Shareholders' equity, beginning of period at Dec. 31, 2011	$9,863,351	$2,223	$13,670,420	($3,952,842)	$143,550
Common stock, beginning of period (shares) at Dec. 31, 2011	'	2,222,883	'	'	'
Comprehensive income (loss)	'	'	'	'	'
Net loss	-361,436	'	'	-361,436	'
Foreign currency translation adjustment	-24,733	'	'	'	-24,733
Comprehensive loss	-386,169	'	'	'	'
Exercise of common stock options (shares)	'	0	'	'	'
Exercise of common stock options	0	0	0	'	'
Share-based compensation	38,316	'	38,316	'	'
Shareholders' equity, beginning of period at Dec. 31, 2012	9,515,498	2,223	13,708,736	-4,314,278	118,817
Common stock, end of period (shares) at Dec. 31, 2012	2,222,883	2,222,883	'	'	'
Comprehensive income (loss)	'	'	'	'	'
Net loss	-500,005	'	'	-500,005	'
Foreign currency translation adjustment	-3,952	'	'	'	-3,952
Comprehensive loss	-503,957	'	'	'	'
Share-based compensation	20,648	'	20,648	'	'
Share Repurchase & Other (shares)	'	-10,633	'	'	'
Share Repurchase & Other	-17,871	-11	-17,862	2	'
Shareholders' equity, beginning of period at Dec. 31, 2013	$9,014,318	$2,212	$13,711,522	($4,814,281)	$114,865
Common stock, end of period (shares) at Dec. 31, 2013	2,212,250	2,212,250	'	'	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities	'	'
Net earnings (loss)	($500,005)	($361,436)
Adjustments to reconcile net loss to net cash provided by operating activities	'	'
Depreciation and amortization	588,287	584,737
(Gain) loss on disposition of assets	2,529	0
Deferred income taxes	-235,460	108,611
Share-based compensation	20,648	38,316
Casualty gain	0	-443,064
Change in operating assets and liabilities	'	'
Accounts receivable	-30,017	-291,646
Inventories	-66,178	1,375,057
Prepaid expenses and other current assets	-91,918	-207,442
Other assets	-15,946	-4,303
Accounts payable, trade	116,517	-632,973
Accrued liabilities	55,086	44,412
Deferred revenue	450,689	235,083
Net cash provided by operating activities	294,232	445,352
Cash flows from investing activities	'	'
Purchase of property and equipment	-267,055	-805,385
Proceeds from insurance policy	0	625,247
Proceeds from sale of equipment	0	0
Net cash used in investing activities	-267,055	-180,138
Cash flows from financing activities	'	'
Redemption of common stock	-17,872	'
Payments of long-term obligations	-196,678	-182,056
Net cash used in financing activities	-214,550	-182,056
Effect of exchange rate changes on cash flows	36,970	-45,615
Net increase (decrease) in cash and cash equivalents	-150,403	37,543
Cash and cash equivalents at beginning of year	3,896,087	3,858,544
Cash and cash equivalents at end of year	3,745,684	3,896,087
Supplemental cash flow disclosures	'	'
Interest paid	112,887	127,509
Income tax refunds received, net	$169,165	$119,881

Nature_of_Operations_and_Organ

Nature of Operations and Organization	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Operations and Organization	'
	NATURE OF OPERATIONS AND ORGANIZATION
	RBC Life Sciences, Inc. (along with its subsidiaries, sometimes hereinafter referred to collectively as “RBC” or the “Company”) is principally engaged in the marketing and distribution of nutritional supplements and personal care products (collectively “Nutritional Products”) through subsidiaries in the U.S., Canada, Taiwan and, beginning in July, 2013, Hong Kong.  This product line is marketed under the “RBC Life” brand name.  In certain markets, primarily the U.S., Canada, Taiwan and Hong Kong, the Company markets its products through a network of distributors that are referred to as “Associates.”  The Associates are independent contractors who purchase products for personal use, purchase products for resale to retail customers and sponsor other individuals as Associates.  Accordingly, Associates may be product consumers only or they may also seek to derive compensation both from the direct sales of products and from sales generated by sponsored Associates.
	RBC also markets its Nutritional Products in certain international markets through license arrangements.  The licensees are third parties who are granted exclusive rights to distribute RBC products in their respective territories and, for the most part, distribute these products through an independent distributor network in a licensed territory.  Under these arrangements, the independent distributor network in a licensed territory is compensated by the licensee in accordance with a compensation plan similar to the one used by RBC for its Associates.
	In addition to its Nutritional Products, RBC also markets a line of wound care products (“Medical Products”) under the MPM Medical brand name through a U.S. subsidiary.  Medical Products are primarily distributed in the U.S. to hospitals, nursing homes, clinics and pharmacies through traditional medical/surgical supply dealers and pharmaceutical distributors.  Medical Products are used to prevent and treat wounds, and manage pain associated with wounds, in the acute care, long-term care and oncology markets.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation and Reporting - The consolidated financial statements include the accounts of RBC and its wholly owned subsidiaries, RBC Life Sciences USA, Inc., RBC Life Sciences Canada, Inc., RBC Life Sciences Hong Kong Limited and MPM Medical, Inc.  All significant intercompany accounts and transactions have been eliminated.  Subsequent events were evaluated through the issuance date of the financial statements.
	Cash and Cash Equivalents - The Company holds cash deposits in foreign bank accounts from time to time.  At December 31, 2013 and 2012, $366,000 and $71,000, respectively, were held in a Canadian bank, and $354,000 and $322,000, respectively, were held in a Taiwanese bank. At December 31, 2013, $444,000 was held in a Hong Kong bank.  For purposes of the statements of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. The Company includes in its cash and cash equivalents credit card receivables due from its credit card processors.
	The Company maintains certain cash balances at a bank located in the United States which at times may exceed insured limits. The Company maintains an agreement with this bank which provides certain collateral as security against the possibility of losses in excess of insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.
	Accounts Receivable - The Company’s accounts receivable arise in the normal course of business and primarily relate to sales of Medical Products to various businesses and individuals.  Accounts receivable are generally due within 30, 45 or 60 days and are stated at amounts due from customers net of an allowance for doubtful accounts.
	Accounts outstanding longer than the contractual payment terms are considered past due.  The Company determines its allowance by considering a number of factors, including the length of time accounts are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the industry as a whole.  The Company charges accounts receivable against the allowance when they become uncollectible, and any payments subsequently received on such accounts are credited to the allowance for doubtful accounts.
	Inventories - Inventories consisting of raw materials and bulk products, packaging materials and finished goods are stated at the lower of cost or market.  The cost of inventories is determined using the first in, first out method.
	Property and Equipment - Property and equipment are recorded at cost. Depreciation and amortization are provided over the estimated useful lives of the related assets, principally on the straight-line method, ranging from three to 25 years.
	Intangible Assets and Amortization - Goodwill and other intangible assets with indefinite useful lives are not amortized, but are reviewed annually for impairment or when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Intangible assets with finite lives are amortized over their useful lives.  At December 31, 2013 and 2012, the Company’s intangible assets with finite lives consisted of copyrights, trademarks, other registrations and other intangibles, which are amortized over an average life of 19 years.
	The Company has designated year end as the date of its annual goodwill impairment test.  The Company tests goodwill for impairment by comparing the carrying value of a reporting unit, including goodwill, to the fair value of the unit.  Fair value is determined by estimating the present value of future cash flows and the value of comparable companies based on sales multiples.  An impairment loss would be recognized if the carrying value of a reporting unit exceeds the implied fair value.  To date, the Company has not recognized any impairment losses related to the carrying value of its goodwill. See Note L for a discussion of the fair value assumptions used for assessing goodwill for impairment.
	Impairment of Long-Lived Assets - Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
	Stock Splits - On August 9, 2013, the Company completed a 1-for-500 reverse stock split (the "Reverse Split"), whereby each 500 shares of the Company's issued and outstanding shares of common stock, was converted into one whole share of new Common Stock (the "New Common Stock"). No fractional shares were issued in connection with the Reverse Split. In lieu of issuing fractional shares to shareholders in connection with the Reverse Split, the Company will pay $0.1691 per share to shareholders.
	Immediately following the Reverse Split, the Company completed a 50-for-1 forward stock split (the "Forward Split" and together with the Reverse Split, the "Stock Splits") whereby each share of New Common Stock was converted into 50 shares of Common Stock.
	Our common stock began trading at the split-adjusted price on August 12, 2013. All share numbers and per share amounts presented reflect the Stock Splits. Amounts recorded as common stock and additional paid in capital within the Shareholders' Equity section of the Condensed Consolidated Balance Sheets have been restated to reflect the impact of the Stock Splits.
	Revenue Recognition and Deferred Revenue - Sales are recorded when products are shipped, which is the point the risks and rewards of ownership pass to the customer. Sales include amounts billed to customers for shipping and handling and are recorded net of sales taxes.  The Company generally requires a cash or credit card payment at the point of sale for Nutritional Products sold to its Associates.  With regard to orders received from its third-party licensees, the Company generally requires the licensee to make a cash deposit equal to 50% of the order at the time an order is placed, and to pay the remaining 50% when the products are segregated in the Company's warehouse and ready to ship; however, sales are not recognized until the products are shipped. Deposits and payments received for unshipped products are recorded as “deferred revenue.”
	The Company’s agreements with its third-party licensees generally provide that licensees pay to the Company a monthly royalty, which is calculated as a specified percentage of the licensees’ sales, as defined, in the territories covered by the license agreements.  Royalties paid by licensees are recorded as sales and amounted to $1,801,000 and $2,003,000 in 2013 and 2012, respectively.
	Distributor Commissions - Distributor commissions consist primarily of commissions paid to Associates in accordance with the Associate compensation plan.  These commissions are calculated based on the total monthly sales by the Associate and his or her downline organization.  Most commissions are paid to Associates monthly.  Sales incentives paid to Associates that represent rebates are recorded as a reduction of sales rather than distributor commission expense.  Associates can earn rebates if the amount of their personal monthly sales exceeds a threshold amount set forth under the Associate compensation plan.  Associate rebates recorded as a reduction of sales were $281,000 and $272,000 in 2013 and 2012, respectively.
	Casualty Gain. In 2012, the Company recognized a casualty gain in connection with the replacement of the roof of its facility in Irving, Texas and reimbursement for a related claim under a replacement cost insurance policy. The replacement of the roof was necessitated by a hailstorm which occurred in May 2011.
	Income Taxes - The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred income tax assets and liabilities are provided based on the difference between the financial statement and tax bases of assets and liabilities as measured by the currently enacted tax rates in effect for the years in which these differences are expected to reverse. Deferred tax expense or benefit is the result of changes in deferred tax assets and liabilities. An allowance against deferred tax assets is recorded in whole or in part when it is more likely than not that such tax benefits will not be realized.
	At December 31, 2013 and 2012, the Company had no unrecognized tax benefits. The Company’s policy is to record any interest and penalties related to gross unrecognized tax benefits within its provision for income taxes.
	Earnings (Loss) Per Share - Basic earnings (loss) per common share is based upon the weighted average number of common shares outstanding during each period presented. Diluted earnings (loss) per share is based upon the weighted average number of common shares outstanding and, when dilutive, common shares issuable for stock options.
	Accounting Estimates - In preparing financial statements in conformity with accounting principles generally accepted in the U.S. ("US GAAP"), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues during the reporting period.  Actual results could differ from those estimates.
	Financial Instruments - The carrying value of cash, interest-bearing deposits, accounts receivable and payable, accrued liabilities and lines of credit approximate fair value due to the short-term maturities of these assets and liabilities. Fair value of long-term debt is estimated based on interest rates for the same or similar instruments offered having the same or similar maturities and collateral requirements.  At December 31, 2013, fair value of fixed-rate long-term debt was $1,469,000, which was $120,000 above the carrying value of $1,349,000.  At December 31, 2012, fair value of fixed-rate long-term debt was $1,713,000, which was $168,000 above the carrying value of $1,545,000. See Note L for a discussion of the fair value assumptions used for determining the fair value of our fixed-rate long-term debt.
	Segment Information - The Company’s operations involve two operating segments:  the Nutritional Products segment and the Medical Products segment.  Nutritional Products are developed and distributed to a network of independent Associates operating primarily in North America and Southeast Asia and to licensees operating in certain other countries outside of North America and Southeast Asia.  Medical Products are developed and sold primarily throughout the U.S. through medical/surgical supply dealers and pharmaceutical distributors to medical institutions such as hospitals, nursing homes and pharmacies.
	Product Return Policy – Up to one year from the date of purchase, Nutritional Products that are unused and resalable may be returned by an Associate for a refund equal to 100% of the sales price to the Associate less a 10% restocking fee and commissions paid. The return of product by an Associate, other than product damaged at the time of receipt, may result in cancellation of the distributorship. Generally, unused Medical Products may be returned up to six months from date of purchase for a refund equal to 100% of the sales price less a 25% restocking fee.  Returned products damaged during shipment are replaced by the Company.  Nutritional Products purchased by licensees may not be returned to the Company for a refund except in the case of a product defect.
	Advertising - Advertising expense is charged to operations when incurred.  Advertising expenses were $44,000 and $117,000 in 2013 and 2012, respectively.
	Translation of Foreign Currencies - All assets and liabilities of foreign subsidiaries are translated into U.S. dollars at the exchange rate in effect at the consolidated balance sheet date.  Revenue and expense accounts are translated at weighted average exchange rates. Translation gains and losses are reflected as a component of other comprehensive income (loss) in shareholders' equity.  Gains and losses on foreign currency transactions are included in the consolidated statements of operations. In 2013, the Company recorded a loss on foreign currency transactions of $66,000. In 2012, the Company recorded a gain on foreign currency transactions of $40,000.
	Other Comprehensive Income (Loss) – Other comprehensive income (loss) refers to revenues, expenses, gains and losses that under US GAAP are included in comprehensive income (loss) but are excluded from net earnings (loss) as the amounts are recorded directly as an adjustment to shareholders’ equity.  The Company’s other comprehensive income (loss) is attributed to translation gains or losses of foreign currencies.
	Share-Based Compensation – The Company recognizes share-based compensation expense based on the fair value of share-based awards.  Share-based compensation is estimated at the grant date based on the fair value of the awards expected to vest and recognized as expense ratably over the requisite service period of the award. The Company uses the Black-Scholes valuation model to estimate fair value of share-based awards, which requires various assumptions including estimating stock price volatility, risk-free interest rate and expected life.
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("ASU 2013-02"), which provides guidance to update the presentation of reclassifications from comprehensive income to net income in consolidated financial statements. Under this new guidance, an entity is required to provide information about the amounts reclassified out of accumulated other comprehensive income either by the respective line items of net income or by cross-reference to other required disclosures. The new guidance does not change the requirements for reporting net income or other comprehensive income in financial statements. This guidance is effective for fiscal years beginning after December 15, 2012. The Company adopted this guidance effective January 1, 2013. The adoption of this guidance did not have a material effect on the consolidated financial statements.

Accounts_Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Accounts Receivable	'
	ACCOUNTS RECEIVABLE
	At December 31, 2013 and 2012, accounts receivable consist of the following:
		2013			2012
	Accounts receivable
	Trade	$	914,287		$	904,692
	Other	21,000			—
	Total	935,287			904,692
	Less allowance for doubtful accounts	28,000			27,417
	Net accounts receivable	$	907,287		$	877,275
	Changes in the Company’s allowance for doubtful accounts for the years ended December 31, 2013 and 2012 are as follows:
		2013			2012
	Beginning balance	$	27,417		$	29,361
	Bad debt provision	9,926			9,019
	Accounts written off	(9,343		)	(10,963		)
	Ending balance	$	28,000		$	27,417
	One medical/surgical dealer accounts for a significant portion of Medical Products sales. This dealer filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Central District of California in Santa Ana, California on February 24, 2012. See Note M elsewhere in these Notes to Consolidated Financial Statements for further information about this dealer. The total amount receivable from this dealer at December 31, 2013 was approximately $527,000. Approximately $240,000 of this amount represents a pre-petition receivable. While we believe the amounts due from this dealer will be collected in full, we will continue to monitor these proceedings as they progress in order to appropriately assess and enforce our rights in this matter.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	INVENTORIES
	At December 31, 2013 and 2012, inventories consist of the following:
		2013		2012
	Raw materials and bulk products	$	371,863	$	173,450
	Packaging materials	135,138		237,871
	Finished goods	4,634,508		4,673,579
		$	5,141,509	$	5,084,900
	Inventories are stated at the lower of cost or market. The Company reviews products based on expiration date and expected rate of sale to determine if the expected net realizable value of products are less than cost. A valuation reserve is established to reduce the carrying value of those products to their net realizable value. The valuation reserve was approximately $157,000 and $290,000 at December 31, 2013 and December 31, 2012, respectively.

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2013
Prepaid Expense, Current [Abstract]	'
Prepaid Expenses and Other Current Assets	'
	PREPAID EXPENSES AND OTHER CURRENT ASSETS
	At December 31, 2013 and 2012, prepaid expenses and other current assets consist of the following:
		2013		2012
	Advances to Associate	$	339,603	$	—
	Advance payments to suppliers	202,682		223,267
	Certificates of deposit – restricted	79,909		85,357
	Prepaid income taxes	7,349		303,983
	Prepaid insurance and other	164,005		220,851
	Total	$	793,548	$	833,458
	At December 31, 2013 and 2012, the Company held certificates of deposit in the amount of approximately $80,000 and $85,000, respectively, which were pledged to secure surety bonds.
	During 2013, the Company entered into agreements with an Associate to market Nutritional Products in Australia, Hong Kong and other Asian markets. Pursuant to these agreements, the Company made cash advances to this Associate to support marketing activities and fund costs related to the opening of an office in Hong Kong. Also in accordance with the agreements, these advances do not bear interest, and are to be recovered from monthly marketing fees calculated as a percentage of sales that are generated in the Associate's markets.
	On July 30, 2013, the Company was notified by the Associate that he was unable to fulfill certain of his financial obligations under the agreements. The Company deemed this failure to represent a material breach of the agreements. Through July 31, 2013, the Company had advanced funds to this Associate totaling approximately $403,000 (net of marketing fees earned).
	Because the Associate was unable to fulfill his financial obligations related to the operation of the Hong Kong office, the Company has continued to advance funds in order to keep the Hong Kong office in operation. Through December 31, 2013, net advances under the agreements were $620,000, which represents gross advances of $692,000, less $72,000 in marketing fees earned through that date. Gross advances made after July 31, 2013 total approximately $280,000. Due to the risk that not all of the advances will be recovered from marketing fees, advances made after July 31, 2013 are fully reserved, and the related expense is included in general and administrative expense during the period.
	Advances outstanding (net of marketing fees earned and reserves for uncollectible advances) as of December 31, 2013 were approximately $340,000. The Company expects to recover the full amount of the net advances outstanding from marketing fees over the next 12 months and they are classified as a prepaid expense and other current asset. The Company is in discussions to determine the appropriate course of action with respect to this Associate to protect the Company's operations in Australia, Hong Kong and other Asian markets. However, there can be no assurance that the advances will be recovered in accordance with the terms of the existing agreements.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	PROPERTY AND EQUIPMENT
	At December 31, 2013 and 2012, property and equipment consist of the following:
		2013		2012
	Building and improvements	$	3,912,449	$	3,812,692
	Computer software and office equipment	2,592,382		2,444,383
	Warehouse equipment	254,034		234,625
	Automotive equipment	14,717		14,717
		6,773,582		6,506,417
	Less accumulated depreciation and amortization	3,745,677		3,159,216
		3,027,905		3,347,201
	Land	1,141,173		1,141,173
		$	4,169,078	$	4,488,374
	Depreciation expense totaled approximately $582,300, and $578,800 for the years ended December 31, 2013, and 2012, respectively.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill and Other Intangible Assets [Abstract]	'
Goodwill and Other Intangible Assets	'
	GOODWILL AND OTHER INTANGIBLE ASSETS
	The Company measures its goodwill for impairment at the end of each year or in the event of an impairment indicator.  No impairment losses have been recognized as a result of this testing. See Note L for a discussion of the fair value assumptions used for assessing goodwill for impairment.
	Goodwill balances are summarized as follows:
			Gross				Accumulated
			Carrying				Amortization
			Value
	Balance, January 1, 2012		$	3,413,527			$	(1,126,668	)
	Currency translation adjustment		21,778				(10,617		)
	Balance, December 31, 2012		3,435,305				(1,137,285		)
	Currency translation adjustment		(67,442		)		32,880
	Balance, December 31, 2013		$	3,367,863			$	(1,104,405	)
	At December 31, 2013 and 2012, other intangible assets consist of the following:
			2013									2012
			Average		Gross				Accumulated			Average	Gross		Accumulated
			Life		Carrying				Amortization			Life	Carrying		Amortization
			(years)		Value							(years)	Value
	Copyrights, trademarks and other registrations		19		$	99,100			$	(65,405	)	19	$	99,100	$	(60,119	)
	Other		19		12,600				(8,316		)	19	12,600		(7,644		)
					$	111,700			$	(73,721	)		$	111,700	$	(67,763	)
	Amortization expense related to other intangible assets totaled approximately $6,000 for the years ended December 31, 2013 and 2012.  The aggregate estimated amortization expense for other intangible assets is as follows:
	Year ended December 31,
	2014	$	5,957
	2015	5,957
	2016	5,957
	2017	5,957
	2018	5,957
	Thereafter	8,194
		$	37,979

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2013
Accrued Liabilities [Abstract]	'
Accrued Liabilities	'
	ACCRUED LIABILITIES
	At December 31, 2013 and 2012, accrued liabilities consist of the following:
		2013		2012
	Distributor commissions	$	507,365	$	443,707
	Salaries and wages	502,303		499,894
	Sales and property taxes	83,159		69,483
	Medical products sales rebates	35,340		52,611
	Interest	8,711		9,981
	Other	19,940		35,455
	Total	$	1,156,818	$	1,111,131

LongTerm_Obligations

Long-Term Obligations	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Long-Term Obligations	'
	LONG-TERM OBLIGATIONS
	At December 31, 2013 and 2012, long-term obligations consist of the following:
			2013		2012
	Mortgage note payable bearing interest at 7.75%, payable in monthly installments of $25,797 through April 2019, collateralized by land and building, and personally guaranteed by the Company’s CEO and Chairman of the Board of Directors		$	1,348,821	$	1,545,499
	Less – current maturities		212,474		196,678
			$	1,136,347	$	1,348,821
	Long-term obligation payments payable in the next five years are as follows:
	Year ended December 31,
	2014	$	212,474
	2015	229,538
	2016	247,973
	2017	267,889
	2018	289,403
	Thereafter	101,544
		$	1,348,821

ShareBased_Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2013
Share-based Compensation [Abstract]	'
Share-Based Compensation	'
	SHARE-BASED COMPENSATION
	Stock incentive plans - On July 1, 1998, the Company’s shareholders adopted the 1998 Stock Option Plan and reserved 500,000 shares of common stock for issuance under this plan.  Effective September 4, 2003, the Company’s shareholders adopted an amendment and restatement of this plan, which, among other things, increased the number of shares reserved under this plan to 3,500,000. This plan expired July 1, 2008 although options granted under this plan remain outstanding at December 31, 2013.
	On June 1, 2006, the Company’s shareholders adopted the 2006 Stock Incentive Plan (the “2006 Plan”) under which 2,500,000 shares of common stock were reserved for issuance.  The 2006 Plan provides for the issuance of non-qualified stock options, incentive stock options, restricted stock awards and stock appreciation rights, and permits grants to employees, non-employee directors and consultants of the Company.
	Generally, stock options granted under these plans vest over a period from four to five years and have a term of nine years.  Certain stock options granted under these plans were fully vested upon grant and certain options have terms of five years.
	Stock Option Accounting - The Company recognizes share-based compensation expense based on the fair value of share-based awards as estimated at the grant date.  Share-based compensation expense for 2013 and 2012 was approximately $20,600 and $38,300, respectively, and is classified as a general and administrative expense.  Tax benefits related to this expense were immaterial because virtually all share-based compensation resulted from grants of ISOs.  No tax benefit is recorded for an ISO unless upon exercise a disqualifying disposition occurs.  The Company will prospectively record any excess tax benefits from the exercise of stock options as cash flows from financing activities. There were no material excess tax benefits in 2013 or 2012.
	Fair Value - The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:
		Year Ended December 31,
		2013		2012
	Weighted average expected life (years)	4.5		4.5 - 6.0
	Risk-free interest rate	1.40%		0.6% - 1.0%
	Expected volatility	261.00%		245% - 310%
	Expected dividend yield	—%		—%
	The weighted average expected life is based on the option term.  The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option.  The expected volatility is based on historical volatility rates.  The expected dividend yield is 0.0% since the Company has no history of paying dividends and currently has no plans to do so.
	Stock Option Activity - All share numbers and per share amounts presented reflect the Stock Splits. See Note B for additional information regarding the Stock Splits. A summary of stock option activity for the two years ended December 31, 2013 is as follows:
		Options			Weighted-			Weighted-Average		Aggregate
					Average Exercise			Remaining		Intrinsic
					Price per Share			Contractual Term		Value
								(in years)
	Outstanding on January 1, 2012	119,057			$	3.3
	Granted	11,680			2.4
	Exercised	—			—
	Forfeited/canceled	(44,611	)		1.8
	Outstanding on December 31, 2012	86,126			4
	Granted	2,160			1.17
	Exercised	—			—
	Forfeited/canceled	(18,890	)		3.47
	Outstanding on December 31, 2013	69,396			$	4		4.3		$	—
	Exercisable on December 31, 2013	54,646			$	4.23		3.7		$	—
	A summary of the status of the Company’s non-vested stock options as of December 31, 2013 and 2012 , and changes during the year then ended, is presented below:
		Year Ended December 31,
		2013						2012
		Shares			Weighted Average			Shares		Weighted Average
					Grant Date Fair					Grant Date Fair
					Value per Share					Value per Share
	Non-vested stock options January 1,	19,976			$	2.9		17,991		4.4
	Non-vested stock options granted	2,160			1.14			11,680		2.4
	Vested stock options	(7,386	)		2.92			(8,017	)	4.7
	Forfeited stock options	—			—			(1,678	)	1.7
	Non-vested stock options at December 31,	14,750			$	2.68		19,976		$	2.9
	Additional information related to stock options granted, vested and exercised for the two years ended December 31, 2013 is a follows:
		Year Ended December 31,
		2013				2012
	Grant date fair value of stock options granted	$	2,471			$	27,663
	Grant date fair value of stock options vested	21,586				37,814
	Intrinsic value of stock options exercised	—				—
	As of December 31, 2013, there was approximately $37,000 of total unrecognized compensation cost related to stock option grants. That cost is expected to be recognized over a weighted average period of 1.8 years.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	INCOME TAXES
	The income tax expense (benefit) reconciled to the tax computed at the statutory Federal rate of 34% is as follows:
		Year Ended December 31,
		2013			2012
	Federal income tax expense (benefit) at statutory rate	$	(250,322	)	$	(200,575	)
	State income taxes, net of federal benefit	(755		)	6,490
	Share-based compensation	6,759			10,682
	Effect of foreign operations, net of foreign tax credits	42,340			9,404
	R&D tax credits recognized	(35,417		)	(27,044		)
	Other, net	1,159			(27,447		)
	Income tax expense (benefit)	$	(236,236	)	$	(228,490	)
	Deferred tax assets and liabilities at December 31, 2013 and 2012 are comprised of the following:
		December 31,
		2013			2012
	Deferred tax assets related to:
	Inventories	$	289,818		$	365,087
	Accounts receivable and other assets	9,800			9,596
	Accrued liabilities	89,816			81,647
	Tax loss and tax credit carryforwards	583,787			70,102
	Other	16,349			21,965
		989,570			548,397
	Valuation allowance	(214,479		)	—
	Net deferred tax assets	775,091			548,397
	Deferred tax liabilities related to:
	Property and equipment	(462,221		)	(596,290		)
	Intangible assets	(610,890		)	(606,612		)
	Deferred tax liabilities	(1,073,111		)	(1,202,902		)
	Net deferred tax liabilities	$	(298,020	)	$	(654,505	)
	Net current deferred tax assets	$	429,640		$	462,088
	Net long-term deferred tax liabilities	(727,660		)	(1,116,593		)
		$	(298,020	)	$	(654,505	)
	At December 31, 2013, the Company has U.S. federal net operating loss carryforwards of approximately $401,000 and tax credit carryforwards of approximately $139,000 that begin to expire in 2020, if not utilized. The Company also has net operating loss carryforwards totaling approximately $1,126,000 in Canada which will begin to expire in 2016 if not utilized, and $244,000 in Hong Kong which can be utilized at any time in the future.
	In February 2013, the Canada Revenue Agency completed an audit of the Company's income tax returns for the period 2008-2011. As a result of that audit, the Company and the Canada Revenue Agency agreed to a change in the transfer pricing between the Company's U.S. and Canadian subsidiaries. As a result, net operating losses of approximately $913,000 for the period 2008-2011 were reversed. Because of the history of operating losses in Canada, and the uncertainty related to recovery of the deferred tax assets, a valuation allowance for the full amount of this Canadian deferred tax asset had been established. Accordingly, the write-off of these deferred tax assets did not significantly impact the Company's financial position or results of operations in 2012. Pursuant to review by competent authority between the U.S and Canadian taxing authorities, in November 2013, the Canada Revenue Agency reversed its position, and determined that the aforementioned net operating losses for 2008-2011 should not be reversed. Accordingly, the deferred tax assets were reinstated at December 31, 2013. As noted above, due to the history of operating losses in Canada and the uncertainty related to recovery of these deferred tax assets, the deferred tax assets are fully reserved, with no net impact on the Company's financial position or results of operations.
	The Company files income tax returns in the U.S., Canada and Taiwan on a federal basis and in certain U.S. state jurisdictions. The most significant taxing jurisdiction is the U.S. federal jurisdiction.  The Company’s 2009 through 2013 tax years remain subject to examination by the IRS for U.S. federal tax purposes.  As of December 31, 2013, no tax years were under examination in any taxing jurisdiction.
	Income tax expense (benefit) for continuing operations consists of the following:
		Year Ended December 31,
		2013			2012
	Current
	Federal	$	2,941		$	(353,064	)
	Foreign	(3,717		)	10,206
	Deferred
	Federal	(196,484		)	114,772
	Foreign	(38,976		)	(404		)
	Income tax expense (benefit)	$	(236,236	)	$	(228,490	)

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	FAIR VALUE MEASUREMENTS
	As defined in ASC 820, Fair Value Measurements, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a three-level valuation hierarchy for fair value measurements. These valuation techniques are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect less transparent active market data, as well as internal assumptions. These two types of inputs create the following fair value hierarchy:
	· Level 1-Quoted prices for identical instruments in active markets
	· Level 2-Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose significant inputs are observable and
	· Level 3-Instruments with significant unobservable inputs
	The fair value of our fixed-rate long-term debt as described in the Financial Instruments section under Note B was determined based on quoted prices for similar instruments in active markets, which are considered to be Level 2 inputs within the fair value hierarchy.
	We have also performed the required impairment review related to goodwill, as described in Note B. A fair value-based methodology is used in testing the carrying value of goodwill, utilizing assumptions including: (1) a long-term projection of revenues and expenses; (2) estimated discounted future cash flows; (3) weighted-average cost of capital; (4) expected tax rate and (5) the enterprise value of comparable companies as a percentage of sales. Factors used in the valuation of goodwill include, but are not limited to, management's plans for future operations, recent operating results and discounted projected future cash flows. These factors are considered Level 3 inputs within the fair value hierarchy.

Commitments_and_Contingencies_

Commitments and Contingencies (Notes)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	COMMITMENTS AND CONTINGENCIES
	Leases - The Company leases office and warehouse space and certain equipment using operating leases for various periods through 2018.  Rental expense under non-cancelable operating leases totaled $193,000 and $217,000 in 2013 and 2012, respectively.  Future minimum payments under non-cancelable operating leases are as follows:
	Year ended December 31,
	2014	$	156,039
	2015	134,840
	2016	134,392
	2017	76,866
	2018	3,024
		$	505,161
	Employee Arrangements - The Company has entered into employment agreements with certain of its key executives. In October, 2013, the Company entered into an employment agreement with the Company's Chief Executive Officer, expiring December 31, 2014, which agreement automatically renews for an additional one-year term unless either party provides notice to the other 60 days prior to the last day of the then current term. Among other things, the agreement provides that if employment is terminated for certain reasons set forth in the agreement, which reasons do not include a change of control, the Company will be required to make a severance payment in an amount equal to the greater of (i) the remaining compensation due through the end of the current term or (ii) one-half of the annual base salary. Upon termination of the agreement, the Chief Executive Officer will receive a specified portion of his salary for an additional three-year period for consulting services.
	In August, 2012, the Company entered into an employment agreement with the Company's President, expiring December 31, 2015, which agreement automatically renews for an additional one-year term unless either party provides notice to the other 30 days prior to the last day of the then current term. Among other things, the agreement provides that if employment is terminated for certain reasons set forth in the agreement, which reasons do not include a change of control, the Company will be required to make a severance payment in an amount equal to the greater of (i) the remaining compensation due through the end of the current term or (ii) one-half of the annual base salary. In the event that the Company chooses not to renew the agreement, the President will be entitled to one-half of the annual base salary as severance.
	In January, 2014, the Company entered into an employment agreement with the Company's Chief Financial Officer, expiring December 31, 2014, which agreement automatically renews for an additional one-year term unless either party provides notice to the other 30 days prior to the last day of the then current term. Among other things, the agreement provides that if employment is terminated for certain reasons set forth in the agreement, which reasons do not include a change of control, the Company will be required to make a severance payment in an amount equal to the greater of (i) the remaining compensation due through the end of the current term or (ii) one-half of the annual base salary. In the event that the Company chooses not to renew the agreement, the Chief Financial Officer will be entitled to one-half of the annual base salary as severance.
	In January, 2014, the Company entered into an employment agreement with the Company's Vice President of Sales, expiring December 31, 2014. Among other things, the agreement provides that if employment is terminated for certain reasons set forth in the agreement, which reasons do not include a change of control, the Company will be required to make a severance payment in an amount equal to his monthly base salary for a period of 90 days.
	In December, 2013 and January, 2014, the Company entered into employment agreements with four other officers or members of the executive team, expiring December 31, 2014. The agreements generally replaced agreements which had an expiration date of December 31, 2013. Among other things, the agreements provide that if employment is terminated for certain reasons set forth in the agreements, which reasons do not include a change of control, the Company will be required to make a severance payment in an amount equal to the greater of (i) the remaining compensation due through the end of the current term or (ii) one-half of the annual base salary.
	The Company’s employees can participate in an employee benefit plan under Section 401(k) of the Internal Revenue Code offered through its Professional Employer Organization.  This plan covers employees in the U.S. who are at least 18 years of age and have been employed by the Company longer than three months.  The Company makes discretionary matching contributions equal to 10% of the employees’ contributions.  Total matching contributions made by the Company during 2013 and 2012 were approximately $13,000 and $12,000, respectively.
	Litigation - The Company is from time to time engaged in routine litigation.  The Company regularly reviews all pending litigation matters in which it is involved and establishes reserves deemed appropriate by management.
	One medical/surgical dealer accounts for a significant portion of Medical Products sales. This dealer distributes our Medical Products and provides services primarily to nursing homes, and obtains reimbursement for the price of our products from Medicare.  This dealer accounted for 44% and 53% of Medical Products net sales in 2013 and 2012, respectively.
	On February 27, 2012, we were notified that this dealer filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Central District of California in Santa Ana, California on February 24, 2012. According to its bankruptcy petition, this dealer filed its petition as the most effective means of stabilizing its finances as it resolves a reimbursement guidelines dispute with Medicare, which the dealer believes is improperly withholding payments. The petition states that this dealer relies on Medicare payments for more than 90% of its revenue and that Medicare has currently suspended all of its payments to the dealer. In a press release issued by the dealer at the time of the filing, the dealer stated that the Chapter 11 filing will allow it to continue operating without interruption while it resolves its payment dispute with Medicare as expeditiously as possible. As of February 28, 2014, we had approximately $240,000 in pre-petition accounts receivable that are owed by this dealer. Since the bankruptcy filing, we have continued to fill this dealer's post-petition orders, with payments received in accordance with our normal terms. While we believe the amounts due to us from this dealer will be collected in full, we will continue to monitor these proceedings as they progress in order to appropriately assess and enforce our rights in this matter.

Segments_and_Geographic_Area

Segments and Geographic Area	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segments and Geographic Area	'
	SEGMENTS AND GEOGRAPHIC AREA
	The Company's segments are based on the organization structure that is used by management for making operating and investment decisions and for assessing performance.  Based on this management approach, the Company has two operating segments: Nutritional Products and Medical Products.
	The Nutritional Products segment manufactures and distributes a line of approximately 100 nutritional supplements and personal care products, including herbs, vitamins and minerals, as well as natural skin, hair and body care products.  Nutritional Products are marketed under the “RBC Life” brand name through subsidiaries in the U.S. and Canada, Taiwan, and beginning in July, 2013, Hong Kong.  These products are distributed by a network of independent Associates in certain markets, primarily in the U.S., Canada, Taiwan and Hong Kong, and by licensees operating in certain other international markets.  For the most part, licensees also market the Nutritional Products in their respective territories through a network of independent Associates.
	The Medical Products segment markets a line of over 35 wound care products under the MPM Medical brand name through a U.S. subsidiary operating primarily in the U.S.  The wound care products are distributed to hospitals, nursing homes, home health care agencies, clinics and pharmacies through a network of medical/surgical supply dealers and pharmaceutical distributors.  Medical Products are used to prevent and treat wounds, and manage pain associated with wounds, in the acute care, long-term care and oncology markets.
	The accounting policies of the segments are the same as those described in Note B. The Company evaluates the performance of its segments primarily based on operating profit.  All intercompany transactions have been eliminated, and intersegment revenues are not significant.  In calculating operating profit (loss) for these two segments, administrative expenses incurred that are common to the two segments are allocated on a usage basis.
	Segment information is as follows (in thousands):
		Nutritional Products			Medical Products		Consolidated
	Year ended December 31, 2013
	Net sales	$	19,084		$	6,387	$	25,471
	Depreciation and amortization	527			61		588
	Operating profit (loss)	(792		)	168		(625		)
	Capital expenditures	267			—		267
	Total assets	13,861			3,673		17,534
	Year ended December 31, 2012
	Net sales	$	18,837		$	6,324	$	25,160
	Depreciation and amortization	511			74		585
	Operating profit (loss)	(716		)	252		(464		)
	Capital expenditures	805			—		805
	Total assets	15,011			3,003		18,014
	Financial information summarized geographically based on the customer’s ordering location for the years ended December 31, 2013 and 2012 is listed below (in thousands):
		Net Sales			Long-lived Assets
	Year ended December 31, 2013
	Domestic	$	9,656		$	5,862
	Russia/Eastern Europe	11,657			—
	Canada	1,530			511
	Southeast Asia	2,454			143
	All others	174			—
	Totals	$	25,471		$	6,516
	Year ended December 31, 2012
	Domestic	$	10,548		$	6,229
	Russia/Eastern Europe	11,010			—
	Canada	1,421			545
	Southeast Asia	1,898			86
	All others	283			—
	Totals	$	25,160		$	6,860
	Significant Customers - The Company recorded sales to CCI, a licensee of the Company, in the amount of $11,657,000 and $11,010,000 for the years ended December 31, 2013 and 2012, respectively.  The Company also recorded sales to a medical/surgical dealer (see Note M) in the amount of $2,807,000 and $3,383,000 for the years ended December 31, 2013 and 2012, respectively.  These sales accounted for more than 10% of net sales in these years.  In no other case did a customer of the Company account for more than 10% of net sales for the years ended December 31, 2013 or 2012.

Earnings_Loss_Per_Share

Earnings (Loss) Per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings (Loss) Per Share	'
	LOSS PER SHARE
	Summarized basic and diluted loss per common share were calculated as follows:
		Net Loss			Shares	Per Share
	Year ended December 31, 2013
	Basic loss per common share	$	(500,005	)	2,218,757	($0.23)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(500,005	)	2,218,757	($0.23)
	Year ended December 31, 2012
	Basic loss per common share	$	(361,436	)	2,222,883	($0.16)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(361,436	)	2,222,883	($0.16)
	For 2013 and 2012, the number of stock options that were outstanding but not included in the computation of diluted loss per common share because their exercise price was greater than the average market price of our common stock or were otherwise anti-dilutive, was approximately 75,000 and 103,000, respectively.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	RELATED PARTY TRANSACTIONS
	Debt Guarantees – The Company’s Chairman of the Board has guaranteed a mortgage note of the Company.  The balance of this note was $1,349,000 at December 31, 2013.
	Customer Arrangement – In July 2004, the Company entered into a ten-year exclusive license agreement with CCI, which replaced an expiring five-year exclusive license agreement.  In connection therewith, the Company received a license fee of $65,000, which was recorded as deferred revenue and is being recognized as sales over the term of the agreement.  Deferred revenue associated with CCI’s account, which included (i) deposits received against purchase orders issued to the Company by CCI, (ii) payments received for products held by the Company for shipment to CCI at a later date, and (ii) the unrecognized portion of the license fee, totaled $3,682,000 and $3,212,000 at December 31, 2013 and 2012, respectively. The Company recorded sales to CCI in the amount of $11,657,000 and $11,010,000 for the years ended December 31, 2013 and 2012, respectively.  Pricing for individual products sold to CCI is reviewed periodically by the Company. Implementation of price changes requires 60 days' notice to CCI. Pursuant to the license agreement between CCI and the Company, CCI also paid royalties to the Company for the years ended December 31, 2013 and 2012 in the amount of $1,801,000 and $2,079,000, respectively, which are included in sales.  The president of CCI beneficially owned approximately 18% of the Company’s outstanding common stock at December 31, 2013 and was a member of the Company’s Board of Directors until June 2004.
	Associate Sales and Marketing System - In December 2013, the Company engaged GSAT, Inc. ("GSATi") to develop a new Associate sales and marketing system. The contract contemplates the development and implementation of a new Associate support system, with substantial completion by September, 2014. Anticipated total payments to GSATi under the contract will be approximately $710,000, excluding taxes. Total payments of approximately $76,000 were made to GSATi during 2013. The founder and CEO of GSATi is a member of our Board of Directors.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Data (unaudited)	'
	QUARTERLY FINANCIAL DATA (UNAUDITED)
	Quarterly financial data for the years ended December 31, 2013 and 2012 is summarized as follows:
		Quarter Ended
		31-Mar			30-Jun				30-Sep			31-Dec
		(Unaudited - In thousands, except per share data)
	2013
	Net sales	$	5,691		$	6,694			$	6,640		$	6,446
	Gross profit	2,973			2,971				3,036			3,032
	Net earnings (loss)	(8		)	(147		)		(142		)	(203		)
	Earnings (loss) per share:
	Basic	$	0		$	(0.07	)		$	(0.06	)	$	(0.09	)
	Diluted	$	0		$	(0.07	)		$	(0.06	)	$	(0.09	)
	2012
	Net sales	$	6,068		$	6,549			$	6,713		$	5,830
	Gross profit	3,129			3,455				3,071			2,977
	Net earnings (loss)	(73		)	320			(a)	(328		)	(279		)
	Earnings (loss) per share:
	Basic	$	(0.03	)	$	0.14		(a)	$	(0.15	)	$	(0.13	)
	Diluted	$	(0.03	)	$	0.15		(a)	$	(0.15	)	$	(0.13	)
	(a) In the second quarter of 2012, the Company recognized a casualty gain of approximately $443,000 in connection with the replacement of the roof of its facility in Irving, Texas and reimbursement for a related claim under a replacement cost insurance policy. The replacement of the roof was necessitated by a hailstorm which occurred in May 2011.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Principles of Consolidation and Reporting	'
	Principles of Consolidation and Reporting - The consolidated financial statements include the accounts of RBC and its wholly owned subsidiaries, RBC Life Sciences USA, Inc., RBC Life Sciences Canada, Inc., RBC Life Sciences Hong Kong Limited and MPM Medical, Inc.  All significant intercompany accounts and transactions have been eliminated.  Subsequent events were evaluated through the issuance date of the financial statements.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents - The Company holds cash deposits in foreign bank accounts from time to time.  At December 31, 2013 and 2012, $366,000 and $71,000, respectively, were held in a Canadian bank, and $354,000 and $322,000, respectively, were held in a Taiwanese bank. At December 31, 2013, $444,000 was held in a Hong Kong bank.  For purposes of the statements of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. The Company includes in its cash and cash equivalents credit card receivables due from its credit card processors.
Accounts Receivable	'
	Accounts Receivable - The Company’s accounts receivable arise in the normal course of business and primarily relate to sales of Medical Products to various businesses and individuals.  Accounts receivable are generally due within 30, 45 or 60 days and are stated at amounts due from customers net of an allowance for doubtful accounts.
	Accounts outstanding longer than the contractual payment terms are considered past due.  The Company determines its allowance by considering a number of factors, including the length of time accounts are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the industry as a whole.  The Company charges accounts receivable against the allowance when they become uncollectible, and any payments subsequently received on such accounts are credited to the allowance for doubtful accounts.
Inventories	'
	Inventories - Inventories consisting of raw materials and bulk products, packaging materials and finished goods are stated at the lower of cost or market.  The cost of inventories is determined using the first in, first out method.
Property and Equipment	'
	Property and Equipment - Property and equipment are recorded at cost. Depreciation and amortization are provided over the estimated useful lives of the related assets, principally on the straight-line method, ranging from three to 25 years.
Intangible Assets and Amortization	'
	Intangible Assets and Amortization - Goodwill and other intangible assets with indefinite useful lives are not amortized, but are reviewed annually for impairment or when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Intangible assets with finite lives are amortized over their useful lives.  At December 31, 2013 and 2012, the Company’s intangible assets with finite lives consisted of copyrights, trademarks, other registrations and other intangibles, which are amortized over an average life of 19 years.
	The Company has designated year end as the date of its annual goodwill impairment test.  The Company tests goodwill for impairment by comparing the carrying value of a reporting unit, including goodwill, to the fair value of the unit.  Fair value is determined by estimating the present value of future cash flows and the value of comparable companies based on sales multiples.  An impairment loss would be recognized if the carrying value of a reporting unit exceeds the implied fair value.  To date, the Company has not recognized any impairment losses related to the carrying value of its goodwill.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets - Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
Revenue Recognition and Deferred Revenue	'
	Revenue Recognition and Deferred Revenue - Sales are recorded when products are shipped, which is the point the risks and rewards of ownership pass to the customer. Sales include amounts billed to customers for shipping and handling and are recorded net of sales taxes.  The Company generally requires a cash or credit card payment at the point of sale for Nutritional Products sold to its Associates.  With regard to orders received from its third-party licensees, the Company generally requires the licensee to make a cash deposit equal to 50% of the order at the time an order is placed, and to pay the remaining 50% when the products are segregated in the Company's warehouse and ready to ship; however, sales are not recognized until the products are shipped. Deposits and payments received for unshipped products are recorded as “deferred revenue.”
	The Company’s agreements with its third-party licensees generally provide that licensees pay to the Company a monthly royalty, which is calculated as a specified percentage of the licensees’ sales, as defined, in the territories covered by the license agreements.
Distributor Commissions	'
	Distributor Commissions - Distributor commissions consist primarily of commissions paid to Associates in accordance with the Associate compensation plan.  These commissions are calculated based on the total monthly sales by the Associate and his or her downline organization.  Most commissions are paid to Associates monthly.  Sales incentives paid to Associates that represent rebates are recorded as a reduction of sales rather than distributor commission expense.  Associates can earn rebates if the amount of their personal monthly sales exceeds a threshold amount set forth under the Associate compensation plan
Income Taxes	'
	Income Taxes - The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred income tax assets and liabilities are provided based on the difference between the financial statement and tax bases of assets and liabilities as measured by the currently enacted tax rates in effect for the years in which these differences are expected to reverse. Deferred tax expense or benefit is the result of changes in deferred tax assets and liabilities. An allowance against deferred tax assets is recorded in whole or in part when it is more likely than not that such tax benefits will not be realized.
Earnings (Loss) Per Share	'
	Earnings (Loss) Per Share - Basic earnings (loss) per common share is based upon the weighted average number of common shares outstanding during each period presented. Diluted earnings (loss) per share is based upon the weighted average number of common shares outstanding and, when dilutive, common shares issuable for stock options.
Accounting Estimates	'
	In preparing financial statements in conformity with accounting principles generally accepted in the U.S. ("US GAAP"), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues during the reporting period.  Actual results could differ from those estimates.
Financial Instruments	'
	Financial Instruments - The carrying value of cash, interest-bearing deposits, accounts receivable and payable, accrued liabilities and lines of credit approximate fair value due to the short-term maturities of these assets and liabilities. Fair value of long-term debt is estimated based on interest rates for the same or similar instruments offered having the same or similar maturities and collateral requirements.
Segment Information	'
	Segment Information - The Company’s operations involve two operating segments:  the Nutritional Products segment and the Medical Products segment.  Nutritional Products are developed and distributed to a network of independent Associates operating primarily in North America and Southeast Asia and to licensees operating in certain other countries outside of North America and Southeast Asia.  Medical Products are developed and sold primarily throughout the U.S. through medical/surgical supply dealers and pharmaceutical distributors to medical institutions such as hospitals, nursing homes and pharmacies.
Product Return Policy	'
	Product Return Policy – Up to one year from the date of purchase, Nutritional Products that are unused and resalable may be returned by an Associate for a refund equal to 100% of the sales price to the Associate less a 10% restocking fee and commissions paid. The return of product by an Associate, other than product damaged at the time of receipt, may result in cancellation of the distributorship. Generally, unused Medical Products may be returned up to six months from date of purchase for a refund equal to 100% of the sales price less a 25% restocking fee.  Returned products damaged during shipment are replaced by the Company.  Nutritional Products purchased by licensees may not be returned to the Company for a refund except in the case of a product defect.
Advertising	'
	Advertising - Advertising expense is charged to operations when incurred.
Translation of Foreign Currencies	'
	Translation of Foreign Currencies - All assets and liabilities of foreign subsidiaries are translated into U.S. dollars at the exchange rate in effect at the consolidated balance sheet date.  Revenue and expense accounts are translated at weighted average exchange rates. Translation gains and losses are reflected as a component of other comprehensive income (loss) in shareholders' equity.  Gains and losses on foreign currency transactions are included in the consolidated statements of operations.
Other Comprehensive Income (Loss)	'
	Other Comprehensive Income (Loss) – Other comprehensive income (loss) refers to revenues, expenses, gains and losses that under US GAAP are included in comprehensive income (loss) but are excluded from net earnings (loss) as the amounts are recorded directly as an adjustment to shareholders’ equity.  The Company’s other comprehensive income (loss) is attributed to translation gains or losses of foreign currencies.
Share-based Compensation	'
	Share-Based Compensation – The Company recognizes share-based compensation expense based on the fair value of share-based awards.  Share-based compensation is estimated at the grant date based on the fair value of the awards expected to vest and recognized as expense ratably over the requisite service period of the award. The Company uses the Black-Scholes valuation model to estimate fair value of share-based awards, which requires various assumptions including estimating stock price volatility, risk-free interest rate and expected life.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("ASU 2013-02"), which provides guidance to update the presentation of reclassifications from comprehensive income to net income in consolidated financial statements. Under this new guidance, an entity is required to provide information about the amounts reclassified out of accumulated other comprehensive income either by the respective line items of net income or by cross-reference to other required disclosures. The new guidance does not change the requirements for reporting net income or other comprehensive income in financial statements. This guidance is effective for fiscal years beginning after December 15, 2012. The Company adopted this guidance effective January 1, 2013. The adoption of this guidance did not have a material effect on the consolidated financial statements.

Accounts_Receivable_Tables

Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Schedule of Accounts Receivable	'
	At December 31, 2013 and 2012, accounts receivable consist of the following:
		2013			2012
	Accounts receivable
	Trade	$	914,287		$	904,692
	Other	21,000			—
	Total	935,287			904,692
	Less allowance for doubtful accounts	28,000			27,417
	Net accounts receivable	$	907,287		$	877,275
Schedule of Allowance for Doubtfull Accounts	'
	Changes in the Company’s allowance for doubtful accounts for the years ended December 31, 2013 and 2012 are as follows:
		2013			2012
	Beginning balance	$	27,417		$	29,361
	Bad debt provision	9,926			9,019
	Accounts written off	(9,343		)	(10,963		)
	Ending balance	$	28,000		$	27,417
	One medical/surgical dealer accounts for a significant portion of Medical Products sales. This dealer filed a voluntary petition for protection under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Central District of California in Santa Ana, California on February 24, 2012. See Note M elsewhere in these Notes to Consolidated Financial Statements for further information about this dealer. The total amount receivable from this dealer at December 31, 2013 was approximately $527,000. Approximately $240,000 of this amount represents a pre-petition receivable. While we believe the amounts due from this dealer will be collected in full, we will continue to monitor these proceedings as they progress in order to appropriately assess and enforce our rights in this matter.

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventories	'
	At December 31, 2013 and 2012, inventories consist of the following:
		2013		2012
	Raw materials and bulk products	$	371,863	$	173,450
	Packaging materials	135,138		237,871
	Finished goods	4,634,508		4,673,579
		$	5,141,509	$	5,084,900

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Prepaid Expense, Current [Abstract]	'
Schedule of Prepaid Expenses and Other Current Assets	'
	At December 31, 2013 and 2012, prepaid expenses and other current assets consist of the following:
		2013		2012
	Advances to Associate	$	339,603	$	—
	Advance payments to suppliers	202,682		223,267
	Certificates of deposit – restricted	79,909		85,357
	Prepaid income taxes	7,349		303,983
	Prepaid insurance and other	164,005		220,851
	Total	$	793,548	$	833,458

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Schedule of Property and Equipment	'
	At December 31, 2013 and 2012, property and equipment consist of the following:
		2013		2012
	Building and improvements	$	3,912,449	$	3,812,692
	Computer software and office equipment	2,592,382		2,444,383
	Warehouse equipment	254,034		234,625
	Automotive equipment	14,717		14,717
		6,773,582		6,506,417
	Less accumulated depreciation and amortization	3,745,677		3,159,216
		3,027,905		3,347,201
	Land	1,141,173		1,141,173
		$	4,169,078	$	4,488,374

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Other Intangible Assets [Abstract]	'
Summary of Goodwill Balances	'
	Goodwill balances are summarized as follows:
			Gross				Accumulated
			Carrying				Amortization
			Value
	Balance, January 1, 2012		$	3,413,527			$	(1,126,668	)
	Currency translation adjustment		21,778				(10,617		)
	Balance, December 31, 2012		3,435,305				(1,137,285		)
	Currency translation adjustment		(67,442		)		32,880
	Balance, December 31, 2013		$	3,367,863			$	(1,104,405	)
Schedule of Other Intangible Assets	'
	At December 31, 2013 and 2012, other intangible assets consist of the following:
			2013									2012
			Average		Gross				Accumulated			Average	Gross		Accumulated
			Life		Carrying				Amortization			Life	Carrying		Amortization
			(years)		Value							(years)	Value
	Copyrights, trademarks and other registrations		19		$	99,100			$	(65,405	)	19	$	99,100	$	(60,119	)
	Other		19		12,600				(8,316		)	19	12,600		(7,644		)
					$	111,700			$	(73,721	)		$	111,700	$	(67,763	)
Schedule of Aggregate Estimated Amortization Expense	'
	The aggregate estimated amortization expense for other intangible assets is as follows:
	Year ended December 31,
	2014	$	5,957
	2015	5,957
	2016	5,957
	2017	5,957
	2018	5,957
	Thereafter	8,194
		$	37,979

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Liabilities [Abstract]	'
Schedule of Accrued Liabilities	'
	At December 31, 2013 and 2012, accrued liabilities consist of the following:
		2013		2012
	Distributor commissions	$	507,365	$	443,707
	Salaries and wages	502,303		499,894
	Sales and property taxes	83,159		69,483
	Medical products sales rebates	35,340		52,611
	Interest	8,711		9,981
	Other	19,940		35,455
	Total	$	1,156,818	$	1,111,131

LongTerm_Obligations_Tables

Long-Term Obligations (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of Long-term Obligations	'
	At December 31, 2013 and 2012, long-term obligations consist of the following:
			2013		2012
	Mortgage note payable bearing interest at 7.75%, payable in monthly installments of $25,797 through April 2019, collateralized by land and building, and personally guaranteed by the Company’s CEO and Chairman of the Board of Directors		$	1,348,821	$	1,545,499
	Less – current maturities		212,474		196,678
			$	1,136,347	$	1,348,821
Schedule of Maturities of Long-term Debt	'
	Long-term obligation payments payable in the next five years are as follows:
	Year ended December 31,
	2014	$	212,474
	2015	229,538
	2016	247,973
	2017	267,889
	2018	289,403
	Thereafter	101,544
		$	1,348,821

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation [Abstract]	'
Schedule of Fair Value of Option Grants	'
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:
		Year Ended December 31,
		2013		2012
	Weighted average expected life (years)	4.5		4.5 - 6.0
	Risk-free interest rate	1.40%		0.6% - 1.0%
	Expected volatility	261.00%		245% - 310%
	Expected dividend yield	—%		—%
Schedule of Stock Option Activity	'
	A summary of stock option activity for the two years ended December 31, 2013 is as follows:
		Options			Weighted-			Weighted-Average		Aggregate
					Average Exercise			Remaining		Intrinsic
					Price per Share			Contractual Term		Value
								(in years)
	Outstanding on January 1, 2012	119,057			$	3.3
	Granted	11,680			2.4
	Exercised	—			—
	Forfeited/canceled	(44,611	)		1.8
	Outstanding on December 31, 2012	86,126			4
	Granted	2,160			1.17
	Exercised	—			—
	Forfeited/canceled	(18,890	)		3.47
	Outstanding on December 31, 2013	69,396			$	4		4.3		$	—
	Exercisable on December 31, 2013	54,646			$	4.23		3.7		$	—
Schedule of Nonvested Share Activity	'
	A summary of the status of the Company’s non-vested stock options as of December 31, 2013 and 2012 , and changes during the year then ended, is presented below:
		Year Ended December 31,
		2013						2012
		Shares			Weighted Average			Shares		Weighted Average
					Grant Date Fair					Grant Date Fair
					Value per Share					Value per Share
	Non-vested stock options January 1,	19,976			$	2.9		17,991		4.4
	Non-vested stock options granted	2,160			1.14			11,680		2.4
	Vested stock options	(7,386	)		2.92			(8,017	)	4.7
	Forfeited stock options	—			—			(1,678	)	1.7
	Non-vested stock options at December 31,	14,750			$	2.68		19,976		$	2.9
Schedule of Grant Date Intrinsic Value	'
	Additional information related to stock options granted, vested and exercised for the two years ended December 31, 2013 is a follows:
		Year Ended December 31,
		2013				2012
	Grant date fair value of stock options granted	$	2,471			$	27,663
	Grant date fair value of stock options vested	21,586				37,814
	Intrinsic value of stock options exercised	—				—

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Reconciliation to tax computed at Federal stautory rate	'
	The income tax expense (benefit) reconciled to the tax computed at the statutory Federal rate of 34% is as follows:
		Year Ended December 31,
		2013			2012
	Federal income tax expense (benefit) at statutory rate	$	(250,322	)	$	(200,575	)
	State income taxes, net of federal benefit	(755		)	6,490
	Share-based compensation	6,759			10,682
	Effect of foreign operations, net of foreign tax credits	42,340			9,404
	R&D tax credits recognized	(35,417		)	(27,044		)
	Other, net	1,159			(27,447		)
	Income tax expense (benefit)	$	(236,236	)	$	(228,490	)
Deferred tax assets and liabilities	'
	Deferred tax assets and liabilities at December 31, 2013 and 2012 are comprised of the following:
		December 31,
		2013			2012
	Deferred tax assets related to:
	Inventories	$	289,818		$	365,087
	Accounts receivable and other assets	9,800			9,596
	Accrued liabilities	89,816			81,647
	Tax loss and tax credit carryforwards	583,787			70,102
	Other	16,349			21,965
		989,570			548,397
	Valuation allowance	(214,479		)	—
	Net deferred tax assets	775,091			548,397
	Deferred tax liabilities related to:
	Property and equipment	(462,221		)	(596,290		)
	Intangible assets	(610,890		)	(606,612		)
	Deferred tax liabilities	(1,073,111		)	(1,202,902		)
	Net deferred tax liabilities	$	(298,020	)	$	(654,505	)
	Net current deferred tax assets	$	429,640		$	462,088
	Net long-term deferred tax liabilities	(727,660		)	(1,116,593		)
		$	(298,020	)	$	(654,505	)
Income tax expense (benefit) for continuing operations	'
	Income tax expense (benefit) for continuing operations consists of the following:
		Year Ended December 31,
		2013			2012
	Current
	Federal	$	2,941		$	(353,064	)
	Foreign	(3,717		)	10,206
	Deferred
	Federal	(196,484		)	114,772
	Foreign	(38,976		)	(404		)
	Income tax expense (benefit)	$	(236,236	)	$	(228,490	)

Commitments_and_Contingencies_1

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases	'
	uture minimum payments under non-cancelable operating leases are as follows:
	Year ended December 31,
	2014	$	156,039
	2015	134,840
	2016	134,392
	2017	76,866
	2018	3,024
		$	505,161

Segments_and_Geographic_Area_T

Segments and Geographic Area (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Information	'
	Segment information is as follows (in thousands):
		Nutritional Products			Medical Products		Consolidated
	Year ended December 31, 2013
	Net sales	$	19,084		$	6,387	$	25,471
	Depreciation and amortization	527			61		588
	Operating profit (loss)	(792		)	168		(625		)
	Capital expenditures	267			—		267
	Total assets	13,861			3,673		17,534
	Year ended December 31, 2012
	Net sales	$	18,837		$	6,324	$	25,160
	Depreciation and amortization	511			74		585
	Operating profit (loss)	(716		)	252		(464		)
	Capital expenditures	805			—		805
	Total assets	15,011			3,003		18,014
Summary of Financial Information by Geographic Segment	'
	Financial information summarized geographically based on the customer’s ordering location for the years ended December 31, 2013 and 2012 is listed below (in thousands):
		Net Sales			Long-lived Assets
	Year ended December 31, 2013
	Domestic	$	9,656		$	5,862
	Russia/Eastern Europe	11,657			—
	Canada	1,530			511
	Southeast Asia	2,454			143
	All others	174			—
	Totals	$	25,471		$	6,516
	Year ended December 31, 2012
	Domestic	$	10,548		$	6,229
	Russia/Eastern Europe	11,010			—
	Canada	1,421			545
	Southeast Asia	1,898			86
	All others	283			—
	Totals	$	25,160		$	6,860

Earnings_Loss_Per_Share_Tables

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Basic and Diluted Earnings (Loss) Per Common Share	'
	Summarized basic and diluted loss per common share were calculated as follows:
		Net Loss			Shares	Per Share
	Year ended December 31, 2013
	Basic loss per common share	$	(500,005	)	2,218,757	($0.23)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(500,005	)	2,218,757	($0.23)
	Year ended December 31, 2012
	Basic loss per common share	$	(361,436	)	2,222,883	($0.16)
	Effect of dilutive stock options	—			—
	Diluted loss per common share	$	(361,436	)	2,222,883	($0.16)

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information	'
	Quarterly financial data for the years ended December 31, 2013 and 2012 is summarized as follows:
		Quarter Ended
		31-Mar			30-Jun				30-Sep			31-Dec
		(Unaudited - In thousands, except per share data)
	2013
	Net sales	$	5,691		$	6,694			$	6,640		$	6,446
	Gross profit	2,973			2,971				3,036			3,032
	Net earnings (loss)	(8		)	(147		)		(142		)	(203		)
	Earnings (loss) per share:
	Basic	$	0		$	(0.07	)		$	(0.06	)	$	(0.09	)
	Diluted	$	0		$	(0.07	)		$	(0.06	)	$	(0.09	)
	2012
	Net sales	$	6,068		$	6,549			$	6,713		$	5,830
	Gross profit	3,129			3,455				3,071			2,977
	Net earnings (loss)	(73		)	320			(a)	(328		)	(279		)
	Earnings (loss) per share:
	Basic	$	(0.03	)	$	0.14		(a)	$	(0.15	)	$	(0.13	)
	Diluted	$	(0.03	)	$	0.15		(a)	$	(0.15	)	$	(0.13	)

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details) (USD $)	0 Months Ended	7 Months Ended	12 Months Ended
	Aug. 09, 2013	Jul. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
			segment
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Cash and cash equivalents	'	'	$3,745,684	$3,896,087	$3,858,544
Net advances under the agreement	'	403,000	620,000	'	'
Marketing fees	'	'	72,000	'	'
Intangible Assets useful life	'	'	'19 years	'	'
Reverse stock split conversion ratio	50000.00%	'	'	'	'
Common stock par value (in dollars per share)	'	'	$0.00	$0.00	'
Stock split cash paid per share (usd per share)	0.1691	'	'	'	'
Conversion ratio	50	'	'	'	'
Cash deposit required from third-party licensees at time of order (percent)	'	'	50.00%	'	'
Cash deposit required from third-party licensees when ready to ship, percent of order	'	'	50.00%	'	'
Royalty revenue	'	'	1,801,000	2,003,000	'
Distributor commissions	'	'	281,000	272,000	'
Fair value of fixed-rate long-term debt	'	'	1,469,000	1,713,000	'
Amount fair value exceeds carrying value	'	'	120,000	168,000	'
Carrying amount of fixed-rate long-term debt	'	'	1,348,821	1,545,000	'
Number of operating segments	'	'	2	'	'
Advertising expense	'	'	44,000	117,000	'
Foreign Currency Transaction Gain (Loss), before Tax	'	'	66,000	-40,000	'
Nutritional Products [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Duration resaleable returned items are fully refunded	'	'	'1 year	'	'
Refund percent of sales price	'	'	100.00%	'	'
Restocking fee (percent)	'	'	10.00%	'	'
Medical Products [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Duration resaleable returned items are fully refunded	'	'	'6 months	'	'
Refund percent of sales price	'	'	100.00%	'	'
Restocking fee (percent)	'	'	25.00%	'	'
HONG KONG [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Cash and cash equivalents	'	'	444,000	'	'
TAIWAN, PROVINCE OF CHINA	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Cash and cash equivalents	'	'	354,000	322,000	'
Canada [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Cash and cash equivalents	'	'	$366,000	$71,000	'
Minimum [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment estimated useful lives	'	'	'3 years	'	'
Maximum [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment estimated useful lives	'	'	'25 years	'	'

Accounts_Receivable_Details

Accounts Receivable (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable	$935,287	$904,692
Less allowance for doubtful accounts	28,000	27,417
Net accounts receivable	907,287	877,275
Allowance for Doubtful Accounts Receivable [Roll Forward]	'	'
Allowance for doubtful accounts, beginning balance	27,417	29,361
Bad debt provision	9,926	9,019
Accounts written off	-9,343	-10,963
Allowance for doubtful accounts, ending balance	28,000	27,417
Accounts receivable from major customer in bankruptcy court	527,000	'
Pre-Petition accounts receivable from major customer in bankruptcy court	240,000	'
Trade [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable	914,287	904,692
Other [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable	$21,000	$0

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]	'	'
Raw materials and bulk products	$371,863	$173,450
Packaging materials	135,138	237,871
Finished goods	4,634,508	4,673,579
Inventories	5,141,509	5,084,900
Valuation allowance	$157,000	$290,000

Prepaid_Expenses_and_Other_Cur2

Prepaid Expenses and Other Current Assets (Details) (USD $)	5 Months Ended	7 Months Ended	12 Months Ended
	Dec. 31, 2013	Jul. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Prepaid Expense, Current [Abstract]	'	'	'	'
Advances to Associate	$339,603	'	$339,603	$0
Advance payments to suppliers	202,682	'	202,682	223,267
Certificates of deposit b restricted	79,909	'	79,909	85,357
Prepaid income taxes	7,349	'	7,349	303,983
Prepaid insurance and other	164,005	'	164,005	220,851
Total	793,548	'	793,548	833,458
Certificates of deposit	80,000	'	80,000	85,000
Net advances under the agreement	'	403,000	620,000	'
Gross advances to associates	280,000	'	692,000	'
Marketing fees	'	'	$72,000	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, net	$4,169,078	$4,488,374
Depreciation expense	582,300	578,800
Building and improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	3,912,449	3,812,692
Computer software and office equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	2,592,382	2,444,383
Warehouse equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	254,034	234,625
Automotive equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	14,717	14,717
Depreciable assets [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	6,773,582	6,506,417
Less: accumulated depreciation	3,745,677	3,159,216
Property and equipment, net	3,027,905	3,347,201
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, net	$1,141,173	$1,141,173

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Summary of Goodwill Balances) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Roll Forward]	'	'
Gross Carrying Value, Beginning Balance	$3,435,305	$3,413,527
Gross Carrying Value, Currency translation adjustment	-67,442	21,778
Gross Carrying Value, Ending Balance	3,367,863	3,435,305
Accumulated Amortization, Beginning Balance	-1,137,285	-1,126,668
Currency translation adjustment	32,880	-10,617
Accumulated Amortization, Beginning Balance	($1,104,405)	($1,137,285)

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets (Summary of Other Intangible Assets) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Average Life (years)	'19 years	'
Gross Carrying Value	$111,700	$111,700
Accumulated Amortization	-73,721	-67,763
Amortization expense	6,000	6,000
Copyrights, trademarks and other registrations [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Average Life (years)	'19 years	'19 years
Gross Carrying Value	99,100	99,100
Accumulated Amortization	-65,405	-60,119
Other [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Average Life (years)	'19 years	'19 years
Gross Carrying Value	12,600	12,600
Accumulated Amortization	($8,316)	($7,644)

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets (Aggregate Estimated Amortization) (Details) (USD $)	Dec. 31, 2013
Goodwill and Other Intangible Assets [Abstract]	'
2013	$5,957
2014	5,957
2015	5,957
2016	5,957
2017	5,957
Thereafter	8,194
Aggregate estimated amortization expense	$37,979

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accrued Liabilities [Abstract]	'	'
Distributor commissions	$507,365	$443,707
Salaries and wages	502,303	499,894
Sales and property taxes	83,159	69,483
Medical products sales rebates	35,340	52,611
Interest	8,711	9,981
Other	19,940	35,455
Total	$1,156,818	$1,111,131

LongTerm_Obligations_Details

Long-Term Obligations (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Debt Disclosure [Abstract]	'	'
Mortgage note payable bearing interest at 7.75%, payable in monthly installments of $25,797 through April 2019, collateralized by land and building, and personally guaranteed by the Companybs CEO and Chairman of the Board of Directors	$1,348,821	$1,545,499
Current maturities of long-term obligations	212,474	196,678
Long-term obligations, less current maturities	1,136,347	1,348,821
Interest rate (as a percentage)	7.75%	'
Monthly installment payments	25,797	'
Long-term Debt, Fiscal Year Maturity [Abstract]	'	'
2013	212,474	'
2014	229,538	'
2015	247,973	'
2016	267,889	'
2017	289,403	'
Thereafter	101,544	'
Total long-term debt	$1,348,821	$1,545,000

ShareBased_Compensation_Summar

Share-Based Compensation (Summary of Fair Value of Option Grants) (Details) (USD $)

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Sep. 04, 2003

Jul. 01, 1998

Jun. 01, 2006

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Stock Options [Member]

Stock Options [Member]

1998 Stock Option Plan [Member]

1998 Stock Option Plan [Member]

2006 Stock Incentive Plan [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares reserved

'

'

'

'

3,500,000

500,000

2,500,000

'

'

'

'

'

'

Award vesting period

'

'

'4 years

'

'

'

'

'

'

'

'

'5 years

'

Award term period

'

'

'

'

'

'

'

'

'5 years

'

'

'9 years

'

Share-based compensation expense

$20,600

$38,300

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average expected life (years)

'4 years 6 months

'

'

'

'

'

'

'4 years 6 months

'

'

'6 years

'

'

Risk-free interest rate

'

'

1.40%

'

'

'

'

'

'

0.60%

'

'

1.00%

Expected volatility

'

'

261.00%

'

'

'

'

'

'

2.00%

'

'

3.10%

Expected dividend yield

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

ShareBased_Compensation_Summar1

Share-Based Compensation (Summary of Stock Option Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Options, Outstanding [Roll Forward]	'	'
Options, Beginning Balance Outstanding	86,126	119,057
Options, Granted	2,160	11,680
Options, Exercised	0	0
Options, Forfeited/canceled	-18,890	-44,611
Options, Ending Balance Outstanding	69,396	86,126
Options, Exercisable	54,646	'
Outstanding, Weighted-Average Exercise Price per Share [Roll Forward]	'	'
Weighted-Average Exercise Price per Share, Beginning Balance Outstanding	$4	$3.30
Weighted-Average Exercise Price per Share, Granted	$1.17	$2.40
Weighted-Average Exercise Price per Share, Exercised	$0	$0
Weighted-Average Exercise Price per Share, Forfeited/canceled	$3.47	$1.80
Weighted-Average Exercise Price per Share, Ending Balance Outstanding	$4	$4
Weighted-Average Exercise Price per Share, Exercisable	$4.23	'
Weighted-Average Remaining Contractual Term, Outstanding	'4 years 3 months 18 days	'
Weighted Average Grant Date Fair Value per Share, Vested stock options	$2.92	$4.70
Weighted-Average Remaining Contractual Term, Exercisable	'3 years 8 months 12 days	'
Aggregate Intrinsic Value, Outstanding	$0	'
Aggregate Intrinsic Value, Exercisable	$0	'

ShareBased_Compensation_Summar2

Share-Based Compensation (Summary of Non-vested Stock Options) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Non-vested Stock Options, Number of Shares [Roll Forward]	'	'
Shares, Non-vested stock options, Beginning Balance	19,976	17,991
Shares, Non-vested stock options granted	2,160	11,680
Shares, Vested stock options	-7,386	-8,017
Shares, Forfeited stock options	0	-1,678
Shares, Non-vested stock options, Ending Balance	14,750	19,976
Non-vested Stock Options, Weighted Average Grant Date Fair Value [Roll Forward]	'	'
Weighted Average Grant Date Fair Value per Share, Non-vested stock options, Beginning Balance	$2.90	$4.40
Weighted Average Grant Date Fair Value per Share, Non-vested stock options granted	$1.14	$2.40
Weighted Average Grant Date Fair Value per Share, Vested stock options	$2.92	$4.70
Weighted Average Grant Date Fair Value per Share, Forfeited stock options	$0	$1.70
Weighted Average Grant Date Fair Value per Share, Non-vested stock options, Ending Balance	$2.68	$2.90

ShareBased_Compensation_Value_

Share-Based Compensation (Value of Stock Options) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Grant date fair value of stock options granted	$2,471	$27,663
Grant date fair value of stock options vested	21,586	37,814
Intrinsic value of stock options exercised	0	0
Total unrecognized compensation cost related to stock option grants	$37,000	'
Period for recognition	'1 year 10 months	'

Income_TaxesReconciliation_Det

Income Taxes-Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Federal statutory income tax rate (percent)	34.00%	'
Income Tax Expense (Benefit), Income Tax Reconciliation [Abstract]	'	'
Federal income tax expense (benefit) at statutory rate	($250,322)	($200,575)
State income taxes, net of federal benefit	-755	6,490
Share-based compensation	6,759	10,682
Effect of foreign operations, net of foreign tax credits	42,340	9,404
R&D tax credits recognized	-35,417	-27,044
Other, net	1,159	-27,447
Income tax expense (benefit)	($236,236)	($228,490)

Income_TaxesDeferred_Tax_Asset

Income Taxes-Deferred Tax Assets (Details) (USD $)	48 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets related to:	'	'	'
Inventories	'	$289,818	$365,087
Accounts receivable and other assets	'	9,800	9,596
Accrued liabilities	'	89,816	81,647
Tax loss and tax credit carryforwards	'	583,787	70,102
Other	'	16,349	21,965
Deferred tax assets, gross	'	989,570	548,397
Valuation allowance	'	-214,479	0
Net deferred tax assets	'	775,091	548,397
Deferred tax liabilities related to:	'	'	'
Property and equipment	'	-462,221	-596,290
Intangible assets	'	-610,890	-606,612
Deferred tax liabilities	'	-1,073,111	-1,202,902
Net deferred tax liabilities	'	-298,020	-654,505
Net current deferred tax assets	'	429,640	462,088
Net long-term deferred tax liabilities	'	-727,660	-1,116,593
U.S. Federal net operating loss carryforward	'	401,000	'
Operating Income (Loss)	913,000	'	'
Domestic Tax Authority [Member]	'	'	'
Deferred tax liabilities related to:	'	'	'
Operating loss carryforwards, subject to expiration	'	139,000	'
Canada [Member] | Foreign Tax Authority [Member]	'	'	'
Deferred tax liabilities related to:	'	'	'
Operating loss carryforwards, subject to expiration	'	1,126,000	'
HONG KONG [Member] | Foreign Tax Authority [Member]	'	'	'
Deferred tax liabilities related to:	'	'	'
Operating loss carryforwards, subject to expiration	'	$244,000	'

Income_TaxesComponents_of_Inco

Income Taxes-Components of Income Tax Expense (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Components of Income Tax Expense (Benefit) [Abstract]	'	'
Current Federal	$2,941	($353,064)
Current Foreign	-3,717	10,206
Deferred Federal	-196,484	114,772
Deferred Foreign	-38,976	-404
Income tax expense (benefit)	($236,236)	($228,490)

Commitments_and_ContingenciesL

Commitments and Contingencies-Leases (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]	'	'
Rent expense	$193,000	$217,000
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'	'
2013	156,039	'
2014	134,840	'
2015	134,392	'
2016	76,866	'
2017	3,024	'
Total future minimum payments due	$505,161	'

Commitments_and_ContingenciesE

Commitments and Contingencies-Employee Arrangements (Details) (USD $)	12 Months Ended						1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2011
			Chief executive officer [Member]	President [Member]	Chief financial officer [Member]	Vice President of Sales [Member]	Other Executives [Member]
							agreement
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]	'	'	'	'	'	'	'
Additional term duration	'	'	'1 year	'1 year	'1 year	'	'
Supplemental Unemployment Benefits, Duration of Salary Continuation	'	'	'	'	'	'90 days	'
Salary continuation, percent of annual base salary	'	'	50.00%	50.00%	50.00%	'	'
Salary continuation duration	'	'	'3 years	'	'	'	'
Number of employment agreements	'	'	'	'	'	'	4
Eligibility age requirement	'18 years	'	'	'	'	'	'
Requisite service period	'P3M	'	'	'	'	'	'
Employer matching contribution, percent	10.00%	'	'	'	'	'	'
Cost recognized	$13,000	$12,000	'	'	'	'	'

Commitments_and_ContingenciesL1

Commitments and Contingencies-Litigation (Details) (USD $)	12 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Feb. 28, 2014	Dec. 31, 2013	Dec. 31, 2012
		Subsequent Event [Member]	Medical Products [Member]	Medical Products [Member]
Loss Contingencies [Line Items]	'	'	'	'
Concentration risk (percent)	'	'	44.00%	53.00%
Concentration risk of major customer (percent)	90.00%	'	'	'
Pre-Petition accounts receivable from major customer in bankruptcy court	$240	$240	'	'

Segments_and_Geographic_Area_S

Segments and Geographic Area (Summary of Segment Information) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
									segment
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Number of operating segments	'	'	'	'	'	'	'	'	2	'
Net sales	$6,446	$6,640	$6,694	$5,691	$6,000	$7,000	$7,000	$6,000	$25,470,934	$25,160,172
Depreciation and amortization	'	'	'	'	'	'	'	'	588,287	584,737
Operating profit (loss)	'	'	'	'	'	'	'	'	-624,624	-463,593
Capital expenditures	'	'	'	'	'	'	'	'	267,055	805,385
Total assets	17,533,510	'	'	'	18,014,421	'	'	'	17,533,510	18,014,421
Nutritional Products [Member]	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Number of products	'	'	'	'	'	'	'	'	100	'
Net sales	'	'	'	'	'	'	'	'	19,084,000	18,837,000
Depreciation and amortization	'	'	'	'	'	'	'	'	527,000	511,000
Operating profit (loss)	'	'	'	'	'	'	'	'	-792,000	-716,000
Capital expenditures	'	'	'	'	'	'	'	'	267,000	805,000
Total assets	13,861,000	'	'	'	15,011,000	'	'	'	13,861,000	15,011,000
Medical Products [Member]	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Number of products	'	'	'	'	'	'	'	'	40	'
Net sales	'	'	'	'	'	'	'	'	6,387,000	6,324,000
Depreciation and amortization	'	'	'	'	'	'	'	'	61,000	74,000
Operating profit (loss)	'	'	'	'	'	'	'	'	168,000	252,000
Capital expenditures	'	'	'	'	'	'	'	'	0	0
Total assets	$3,673,000	'	'	'	$3,003,000	'	'	'	$3,673,000	$3,003,000

Segments_and_Geographic_Area_S1

Segments and Geographic Area (Summary of Financial Information by Geographic Location) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	$6,446	$6,640	$6,694	$5,691	$6,000	$7,000	$7,000	$6,000	$25,470,934	$25,160,172
Long-lived Assets	6,516,000	'	'	'	6,860,000	'	'	'	6,516,000	6,860,000
Domestic [Memeber]	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	9,656,000	10,548,000
Long-lived Assets	5,862,000	'	'	'	6,229,000	'	'	'	5,862,000	6,229,000
Russia/Eastern Europe [Member]	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	11,657,000	11,010,000
Long-lived Assets	0	'	'	'	0	'	'	'	0	0
Canada [Member]	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	1,530,000	1,421,000
Long-lived Assets	511,000	'	'	'	545,000	'	'	'	511,000	545,000
Southeast Asia [Member]	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	2,454,000	1,898,000
Long-lived Assets	143,000	'	'	'	86,000	'	'	'	143,000	86,000
All others [Member]	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	174,000	283,000
Long-lived Assets	$0	'	'	'	$0	'	'	'	$0	$0

Segments_and_Geographic_Area_S2

Segments and Geographic Area (Summary Significant Customers) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	$6,446	$6,640	$6,694	$5,691	$6,000	$7,000	$7,000	$6,000	$25,470,934	$25,160,172
Nutritional Products [Member]	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	19,084,000	18,837,000
Medical Products [Member]	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	6,387,000	6,324,000
Coral Club International, Inc. [Member]	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	11,657,000,000	11,010,000,000
Medical/Surgical Dealer [Member] | Medical Products [Member]	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	$3,000,000	$3,383,000

Earnings_Loss_Per_Share_Detail

Earnings (Loss) Per Share (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]	'	'	'	'	'	'	'	'	'	'
Net earnings (loss)	$0	$0	$0	$0	$0	$0	$0	$0	($500,005)	($361,436)
Net Earnings (Loss), Diluted	'	'	'	'	'	'	'	'	($500,005)	($361,436)
Basic (shares)	'	'	'	'	'	'	'	'	2,218,757	2,222,883
Weighted Average Shares, Effect of dilutive stock options	'	'	'	'	'	'	'	'	0	0
Diluted (shares)	'	'	'	'	'	'	'	'	2,218,757	2,222,883
Basic (usd per share)	($0.09)	($0.06)	($0.07)	$0	($0.13)	($0.15)	$0.14	($0.03)	($0.23)	($0.16)
Diluted (usd per share)	($0.09)	($0.06)	($0.07)	$0	($0.13)	($0.15)	$0.15	($0.03)	($0.23)	($0.16)
Antidilutive stock options excluded from earnings per share calculation	'	'	'	'	'	'	'	'	75,000	103,000

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)

3 Months Ended

12 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Jul. 31, 2004

Jun. 30, 2004

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Coral Club International, Inc. [Member]

Coral Club International, Inc. [Member]

Coral Club International, Inc. [Member]

Coral Club International, Inc. [Member]

Nutritional Products [Member]

Nutritional Products [Member]

Director [Member]

President [Member]

Coral Club International, Inc. [Member]

Employee of Major Customer [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,349,000

'

Duration of license agreement

'

'

'

'

'

'

'

'

'

'

'10 years

'5 years

'

'

'

'

'

'

License costs

'

'

'

'

'

'

'

'

'

'

65,000

'

'

'

'

'

'

'

Unrecognized license fees

'

'

'

'

'

'

'

'

'

'

'

'

3,682,000

3,212,000

'

'

'

'

Net sales

6,446

6,640

6,694

5,691

6,000

7,000

7,000

6,000

25,470,934

25,160,172

'

'

11,657,000,000

11,010,000,000

19,084,000

18,837,000

'

'

Royalty revenue

'

'

'

'

'

'

'

'

1,801,000

2,003,000

'

'

1,801,000

2,079,000

'

'

'

'

Ownership percentage by noncontrolling owners

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18.00%

Anticipated total payments under the contract

710,000

'

'

'

'

'

'

'

710,000

'

'

'

'

'

'

'

'

'

Payments made on contract during period

'

'

'

'

'

'

'

'

$76,000

'

'

'

'

'

'

'

'

'

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'
Gain (Loss) on Casualty	'	'	'	'	'	'	$443,000	'	$0	$443,064
Net sales	6,446	6,640	6,694	5,691	6,000	7,000	7,000	6,000	25,470,934	25,160,172
Gross profit	3,000	3,000	3,000	3,000	3,000	3,000	3,000	3,000	12,011,655	12,631,954
Net earnings (loss)	$0	$0	$0	$0	$0	$0	$0	$0	($500,005)	($361,436)
Basic (usd per share)	($0.09)	($0.06)	($0.07)	$0	($0.13)	($0.15)	$0.14	($0.03)	($0.23)	($0.16)
Diluted (usd per share)	($0.09)	($0.06)	($0.07)	$0	($0.13)	($0.15)	$0.15	($0.03)	($0.23)	($0.16)